• Affiliate Professor, Global Health
  • Affiliate Professor, Biomedical Informatics and Medical Education
  • Professor, Seattle Children's Research Institute
Peter Myler

Seattle, WA
United States

Phone Number: 
206-884-3195
Select from the following:
Biography 

For the past 20 years, my laboratory has been at the forefront of applying genome-scale technologies (next-generation sequencing, mRNA profiling and proteomics) and systems approaches to increase our understanding of the molecular mechanisms underlying transcription in Leishmania and other trypanosomatid parasites, as well as regulation of gene expression during differentiation. I am also PI and director of the Seattle Structural Genomics Center for Infectious Disease (SSGCID), which is funded under a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with the mission using X-ray crystallography, NMR spectroscopy and cryo-electron microscopy to solve the structure of proteins from emerging and re-emerging infectious disease organisms (bacteria, viruses and eukaryotic parasites). This data is made freely available to the scientific community in order to understand molecular function of these targets and to facilitate development of new therapeutics by using structure-guided drug and vaccine design.

Education 
  • PhD (University of Queensland (Australia))
  • BSc (University of Queensland (Australia))
Country Affiliations 
Languages 
  • French
Health Topics 
  • Biodefense Infectious Diseases
  • Genomics
  • Hepatitis
  • Host-Pathogen Interactions
  • Infectious Diseases
  • Influenza
  • Leishmaniasis
  • Malaria
  • Neglected Diseases, Tropical Medicine (incl. Parasites)
  • Pathobiology
  • Pathogenesis
  • Research
  • STDs (other than HIV)
  • TB
Pathobiology research areas 
Expertise 

regulation of gene expression in protozoan parasites

Publications 

Myler PJ, Audleman L, deVos T, Hixson G, Kiser P, Lemley C, Magness C, Rickel E, Sisk E, Sunkin S, Swartzell S, Westlake T, Bastien P, Fu G, Ivens A, Stuart K. (1999) Leishmania major Friedlin chromosome 1 has an unusual distribution of protein-coding genes. Proc Natl Acad Sci USA 96:2902-2906. PubMed:10077609 PMC15867

Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, Sisk E, Rajandream MA, Adlem E, Aert R, Anupama A, Apostolou Z, Attipoe P, Bason N, Bauser C, Beck A, Beverley SM, Bianchettin G, Borzym K, Bothe G, Bruschi CV, Collins M, Cadag E, Ciarloni L, Clayton C, Coulson RM, Cronin A, Cruz AK, Davies RM, De Gaudenzi J, Dobson DE, Duesterhoeft A, Fazelina G, Fosker N, Frasch AC, Fraser A, Fuchs M, Gabel C, Goble A, Goffeau A, Harris D, Hertz-Fowler C, Hilbert H, Horn D, Huang Y, Klages S, Knights A, Kube M, Larke N, Litvin L, Lord A, Louie T, Marra M, Masuy D, Matthews K, Michaeli S, Mottram JC, Muller-Auer S, Munden H, Nelson S, Norbertczak H, Oliver K, O'Neil S, Pentony M, Pohl TM, Price C, Purnelle B, Quail MA, Rabbinowitsch E, Reinhardt R, Rieger M, Rinta J, Robben J, Robertson L, Ruiz JC, Rutter S, Saunders D, Schafer M, Schein J, Schwartz DC, Seeger K, Seyler A, Sharp S, Shin H, Sivam D, Squares R, Squares S, Tosato V, Vogt C, Volckaert G, Wambutt R, Warren T, Wedler H, Woodward J, Zhou S, Zimmermann W, Smith DF, Blackwell JM, Stuart KD, Barrell B, Myler PJ. (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309:436-442. PubMed:16020728 PMC1470643

van Luenen HG, Farris C, Jan S, Genest PA, Tripathi P, Velds A, Kerkhoven RM, Nieuwland M, Haydock A, Ramasamy G, Vainio S, Heidebrecht T, Perrakis A, Pagie L, van Steensel B, Myler PJ, Borst P. (2012) Glucosylated hydroxymethyluracil, DNA base J, prevents transcriptional readthrough in Leishmania. Cell 150:909-921. PubMed:22939620 PMC3684241

Goldman-Pinkovich A, Balno C, Strasser R, Zeituni-Molad M, Bendelak K, Rentsh D, Ephros M, Wiese M, Jardim A, Myler PJ, Zilberstein D (2016) An arginine deprivation response pathway is induced in Leishmania during macrophage invasion. PLoS Pathog 12:e1005494. PubMed:27043018 PMC4846328

Baragaña B, Forte B, Choi R, Nakazawa Hewitt S, Bueren-Calabuig JA, Pisco JP, Peet C, Dranow DM, Robinson DA, Jansen C, Norcross NR, Vinayak S, Anderson M, Brooks CF, Cooper CA, Damerow S, Delves M, Dowers K, Duffy J, Edwards TE, Hallyburton I, Horst BG, Hulverson MA, Ferguson L, Jiménez-Díaz MB, Jumani RS, Lorimer DD, Love MS, Maher S, Matthews H, McNamara CW, Miller P, O'Neill S, Ojo KK, Osuna-Cabello M, Pinto E, Post J, Riley J, Rottmann M, Sanz LM, Scullion P, Sharma A, Shepherd SM, Shishikura Y, Simeons FRC, Stebbins EE, Stojanovski L, Straschil U, Tamaki FK, Tamjar J, Torrie LS, Vantaux A, Witkowski B, Wittlin S, Yogavel M, Zuccotto F, Angulo-Barturen I, Sinden R, Baum J, Gamo FJ, Mäser P, Kyle DE, Winzeler EA, Myler PJ, Wyatt PG, Floyd D, Matthews D, Sharma A, Striepen B, Huston CD, Gray DW, Fairlamb AH, Pisliakov AV, Walpole C, Read KD, Van Voorhis WC, Gilbert IH (2019) Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proc Natl Acad Sci USA 116:7015-7020. PubMed:30894487 PMC6452685